No association was observed between serious infection risk and Janus kinase inhibitor use in patients with immune-mediated inflammatory skin disease.

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

Incyte's infringement lawsuit is claiming that Sun Pharma's drug infringes a US patent (No. 9,662,335) it holds on the use of ...

Lilly and Incyte's already-marketed JAK inhibitor Olumiant (baricitinib) is currently in the lead among drugs for alopecia areata, with a filing due in the second half of this year after two ...

In Europe, there is an oral JAK inhibitor called Bbricitinib, which is approved by the EMA for atopic dermatitis, moderate to severe, but approved in the United States for alopecia areata ...

Maryanne Senna, MD, assistant professor of dermatology at Harvard Medical School, discusses the results of the case and the impact JAK inhibitors have had on the treatment of alopecia areata ...

GCA is an autoimmune condition, predominantly affecting individuals over 50, with the highest incidence between 70 and 80 ...

AbbVie ABBV announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating giant cell arteritis (“GCA”), an autoimmune disease that causes ...

Emkay Global Financial Services, in a client note, described the development as “materially positive,” as it removes a key ...

While some forms of hair loss are irreversible, others can be improved. In our essential guide, we've teamed up with experts ...

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...